Antiemetic efficacy and safety of granisetron or palonosetron alone and in combination with a corticosteroid for ABVD therapy-induced nausea and vomiting

Antiemetic effects and safety of granisetron or palonosetron alone and in combination with a corticosteroid against chemotherapy-induced nausea and vomiting (CINV) were retrospectively evaluated in patients with Hodgkin lymphoma receiving adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) th...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical health care and sciences 2018-01, Vol.4 (1), p.1-1, Article 1
Main Authors: Uchida, Mayako, Nakamura, Tsutomu, Hata, Kojiro, Watanabe, Hiroyuki, Mori, Yasuo, Kato, Koji, Kamezaki, Kenjiro, Takenaka, Katsuto, Shiratsuchi, Motoaki, Hosohata, Keiko, Miyamoto, Toshihiro, Akashi, Koichi
Format: Article
Language:English
Subjects:
Analysis
Cancer
Care and treatment
Chemotherapy
Chemotherapy-induced nausea and vomiting
Complete response
Corticosteroid
Delayed phase
Dexamethasone
Granisetron
Hodgkin's disease
Nausea
Palonosetron
Quality of life
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antiemetic effects and safety of granisetron or palonosetron alone and in combination with a corticosteroid against chemotherapy-induced nausea and vomiting (CINV) were retrospectively evaluated in patients with Hodgkin lymphoma receiving adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) therapy. A total of 39 patients were eligible for this study. Before ABVD therapy, granisetron or palonosetron was intravenously administered with or without a corticosteroid (dexamethasone or hydrocortisone) and aprepitant. The proportions of patients with complete control (CC) during the overall (0-120 h after the start of ABVD therapy), acute (0-24 h) and delayed (24-120 h) phases were evaluated. CC was defined as no vomiting and no use of antiemetic rescue medication with only grade 0-1 nausea. Granisetron and palonosetron were administered in 21 and 18 patients, respectively. The CC rate during the acute, delayed and overall phases was not statistically different between the two groups. The CINV was completely controlled during overall phase in 58.3% of patients receiving granisetron or palonosetron in combination with a corticosteroid, whereas in 11.1% of those without co-treatment of a corticosteroid (  
ISSN:2055-0294
2055-0294
DOI:10.1186/s40780-017-0097-4